ABWIZ BIO, INC.
Neutralizing monoclonal antibodies against Machupo virus, using stabilized-trimer immunogens to target multiple epitopes on the viral surface glycoprotein
- Sector
- Biotech
- Total capital
- $1.1M
- Federal grants
- $1.1M
- 4 awards · 2016–2024
- Rank in peer group#274 of 326
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 14 pending · first 2018
- Rank in peer group#80 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Development of Neutralizing Antibodies to Machupo Virus$281K
- Federal grantHealth and Human S · Phase I · Engineering a unique antibody for patients with RA$300K
- Federal grantHealth and Human S · Phase I · Engineering a unique antibody for patients with RA$300K
- Federal grantHealth and Human S · Phase I · Blockade of histamine-releasing factor as a new prophylactic and therapeutic strategy for food allergy$230K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#80 · top 25%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 1 granted of 15- PendingHumanization, Affinity Maturation, And Optimization Methods For Proteins And AntibodiesUSPTOApplication 18683502
- PendingAnti-ige AntibodiesUSPTOApplication 18378125
- GrantedPreparation of Gene-Specific Templates for the Use in Single Primer AmplificationUSPTOUS 9,890,414
Show all 15 patent records
- Humanization, Affinity Maturation, And Optimization Methods For Proteins And AntibodiesOct 24, 2024 · Application 18683502Pending
- Anti-ige AntibodiesJun 6, 2024 · Application 18378125Pending
- Preparation of Gene-Specific Templates for the Use in Single Primer AmplificationFeb 13, 2018 · US 9,890,414Granted
- HUMANIZED ANTIBODIES FOR SARS-CoV-2 AND VARIANTS THEREOFApplication 63431663Pending
- Anti-ige AntibodiesApplication 63414414Pending
- Humanization, Affinity Maturation, And Optimization Methods For Proteins And AntibodiesApplication PCTUS2022040350Pending
- Anti-hrf AntibodiesApplication 63390603Pending
- Humanization and affinity maturation and optimization method of an antibodyApplication 63354010Pending
- Humanization and affinity maturation and optimization method of an antibodyApplication 63232948Pending
- T Regulatory Cells And Uses ThereofApplication PCTUS2014037195Pending
- Preparation Of Gene-specific Templates For The Use In Single Primer AmplificationApplication PCTUS2013072376Pending
- Antibodies Or Fragments Thereof For SARS-COV-2 And Variants ThereofApplication 19137255Pending
- Anti-hrf AntibodiesApplication 18994030Pending
- Antibodies Or Fragments Thereof For SARS-COV-2 And Variants ThereofApplication PCTUS2023083390Pending
- Anti-ige AntibodiesApplication PCTUS2023034765Pending
Related companies, and why
- ZENVAX, LLCSimilar federal contract value in Biotech · null in contracts
- FUSION ENERGY SOLUTIONS, INC. D/B/A SERVA ENERGYSimilar federal contract value in Biotech · null in contracts
- KEYSTONE NANO, INC.Similar federal contract value in Biotech · null in contracts
- SNJ PHARMA INC.Similar federal contract value in Biotech · null in contracts
- IMAGE ANALYST SOFTWARESimilar federal contract value in Biotech · null in contracts
- Eilean TherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .